Even they are used raw or sometimes simply warmed. In many cases, they use them as a sole drug or occasionally
supplemented by other botanicals or substances. They used these to combat common diseases such as migraine, rheumatic or joint pains, acidity, scabies, wounds, injuries, pimples, jaundice constipation, amoebic dysentery, cough, menstrual complaints, stomach-ache, tooth-ache, flatulence, burns, indigestion, eye-burning, fever etc. as well as killer diseases. Conclusion: It was found that some of the information has not so far been available in literature. The method learn more of preparation and mode of action is also simple and convenient. The studies indicated that the knowledge is to be transferred properly by old people to younger generation and should selleck screening library be trained in collection and processing. Key Word(s): 1. African American; 2. Asian; 3. Culinary botanicals; 4. Killer diseases; Presenting Author: MEIYUN KE Additional Authors:
JAN TACK, EAMONN QUIGLEY, ZOU DUOWU, SUCK CHEI CHOI, SOMCHAI LEELAKUSOLVONG, ANDY LIU, JINYONG KIM Corresponding Author: MEIYUN KE Affiliations: Peking Union Medical College Hospital; Ku Leuven Research & Development; The Methodist Hospital and Weill Cornell Medical College; Second Military Medical University; Wonkwang University College of Medicine; Mahidol University; Janssen; Janssen, Asia-Pacific Objective: To assess the efficacy and safety of 12-week prucalopride 2-mg once-daily treatment on chronic constipation (CC)-associated symptoms in Asian and non-Asian women. Methods: Data from 4 Phase 3, randomized, double-blind, and placebo-controlled studies were analyzed. Efficacy was measured as the
percentage of women achieving ≥3 spontaneous complete bowel movements per week (SCBMs/wk) [primary endpoint] and those with an average increase of ≥1 SCBM/wk [secondary see more endpoint] over 12-week treatment. CC-associated symptoms were abdominal bloating, abdominal pain, hard stool, and straining. Symptoms relief was measured as improvement in the validated ‘Patient Assessment of Constipation Symptoms’ questionnaire. Change from baseline in each symptom score was analyzed using an ANCOVA model (treatment, study, and baseline spontaneous bowel movement as factors; baseline symptom score was a covariate for each subgroup). Results: A total of 1596 women (26.6% Asian; 73.4% non-Asian) were included. Significantly more (p < 0.001) prucalopride-treated women had ≥3 SCBMs/wk than placebo-treated women in Asian (34% vs. 11%) and non-Asian subgroups (24.6% vs. 10.6%). The percentage differences (prucalopride minus placebo) of women with ≥3 SCBMs/wk and average increase of ≥1 SCBMs/wk were higher in Asians than non-Asians: 22.9% vs. 14.0% and 29.1% vs. 21.4%, respectively. At baseline, a higher percentage of non-Asian compared to Asian women reported severe/very severe bloating (57.5% vs. 31.8%), abdominal pain (29.6% vs. 9.4%), hard stools (46.4% vs. 34.